A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology

Active, not recruitingOBSERVATIONAL

Enrollment

2,000

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Alzheimer's Disease

Interventions

OTHER

No Intervention

No treatment intervention will be administered.

Trial Locations (3)

Eisai Site #2, District Heights

Eisai Site #1, Lady Lake

Eisai Site #3, Clermont

All Listed Sponsors

lead

Eisai Limited

INDUSTRY

NCT06043700 - A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology | Biotech Hunter | Biotech Hunter